May 2010
Sunday, May 30, 2010
Phase 2 Clinical Trial Data Show Significant Improvements in Outcomes and Symptoms in Advanced Heart Failure Patients Treated with Celladon’s Genetically Targeted Enzyme Replacement Therapy MYDICAR®

Apr 2010
Wednesday, April 28, 2010
Celladon Corp. Announces that MYDICAR® Meets Primary Endpoint in Phase 2 Trial for Treatment of Advanced Heart Failure

Mar 2010
Tuesday, March 23, 2010
Celladon Corporation receives Notice of Allowance by U.S. Patent and Trademark Office for Broad Patent Covering Lead Drug Candidate MYDICAR®

Nov 2009
Tuesday, November 17, 2009
Celladon Corporation Announces Upcoming Presentations at American Heart Association Scientific Sessions 2009
Monday, November 23, 2009
University of Minnesota, in Collaboration with Celladon Corporation, Invent Technology to Speed Development of Treatments in Heart Failure

Sep 2009
Wednesday, September 23, 2009
Celladon's MYDICAR® and Small Molecule SERCA2a Studies in Acute and Chronic Heart Failure Selected One of Windhover’s Top 10 Cardiovascular Programs to Watch

Aug 2009
Monday, August 31, 2009
Celladon Corporation And Momentum Research Complete Enrollment Of MYDICAR® Phase 2 Study Of First-In-Human Gene Transfer To Treat Patients With Advanced Heart Failure

May 2009
Thursday, May 28, 2009
Celladon Provides Mydicar® Program Update Of First-In-Human Trial For Advanced Heart Failure At American Society Of Gene Therapy Annual Meeting

April 2009
Wednesday, April 8, 2009
The Journal of Cardiac Failure Publishes Results  from Celladon Corporation’s First-in-Human   Phase 1/2 Clinical Trial in Advanced Heart  Failure

June 2008
Wednesday, June 18, 2008
First Gene Therapy for Heart Failure Offered at NewYork-Presbyterian Hospital/Columbia University Medical Center

October 2007
October 5, 2007
Experimental Trial is Underway at Local Hospital

May 2007
May 17, 2007
Celladon and Targeted Genetics initiate Phase I clinical trial of Mydicar in patients with heart failure

June 2005
June 20, 2005
Celladon and V-Kardia to Collaborate on Development of Percutaneous Delivery of Gene Therapy for Heart Failure

June 02, 2005
Celladon's collaborators present large animal trial results at the American Society of Gene Therapy Conference in St. Louis, MO.

January 2005
January 04, 2005
Celladon and Targeted Genetics Announce a Collaboration to develop AAV-based gene therapies for congestive heart failure.